Ott CJ, Wu CJ. HDAC Inhibitors Finally Open Up: Chromatin Accessibility Signatures of CTCL. Cancer Cell. 2017;32(1):1-3. doi:10.1016/j.ccell.2017.06.008
Horwitz SM, Koch R, Porcu P, et al. Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood. 2018;131(8):888-898. doi:10.1182/blood-2017-08-802470